Antisense Therapeutics Limited (AU:PER) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics Limited, a biotech firm specializing in rare disease therapies, has updated its corporate presentation, detailing recent advancements and future goals. The presentation, which replaces the one from February, will be used in upcoming investor discussions and at several investor conferences in September 2024. Their lead drug, ATL1102, is currently in an international phase IIb trial for Duchenne Muscular Dystrophy, with results expected in the second half of 2024.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.